CERO - יחס חוב להיוון בספרים CERo Therapeutics Holdings, Inc.

The current financial health of CERo Therapeutics (CERO) is supported by attracted investments, as illustrated by the monitoring of the company's debt-to-equity ratio on the GURU.Markets terminal chart, where the value 0.00 corresponds to the current metric. The project relies on innovative T-cell phagocyte therapy to combat tumors, with the success of these developments ensured by a team of leading experts in immuno-oncology.

This indicator determines the degree of the company's dependence on borrowed capital relative to its own equity capital. The historical trend of the debt-to-equity ratio allows for the filtering of market noise when analyzing net assets. The metric is calculated as the proportion of total liabilities to the market value of equity. A low leverage level is critically important for CERo Therapeutics (CERO). This ensures financial stability during the implementation of costly robotic T-cell modification systems.